Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

6.923 +0.073 (+1.07%)
Streaming Delayed Price Updated: 10:12 AM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
Coya Therapeutics reports mixed data from Phase 2 study of low-dose IL-2 in Alzheimer's, showing safety and potential cognitive benefits in q4wks regimen. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
Coya Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
Coya Therapeutics
100% technical buy signals. 15 new highs and up 43.21% in the last month. 74.87+ Weighted Alpha 
Via Talk Markets
Analyst Expectations for Coya Therapeutics's Future
Via Benzinga
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD,... 
Via Benzinga
COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases
Dr. Howard Burman, Ph.D, CEO and Dr. Arun Swaminathan, CBO, of Coya Therapeutics Inc (NASDAQ: COYA), were guests on Benzinga’s All Access. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
How The Same Treatments May Work For Multiple Neurodegenerative Diseases
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate. 
Via Talk Markets
The Latest Analyst Ratings for Coya Therapeutics
Via Benzinga
Coya Therapeutics: Another Sucess
The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company. 
Via Talk Markets
Why Coya Therapeutics Shares Are Shooting Higher Today
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients  
Via Benzinga
The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth
Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this... 
Via Benzinga
Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close... 
Via Benzinga
Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation
Coya Therapeutics Inc (NASDAQ: COYA) reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
Tesla, Manchester United, Ohmyhome, Target, Coya: Why These 5 Stocks Are Drawing Investor Attention Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Positive Financials Along With Promising Clinical Results – Coya Therapeutics
Howard Berman, Ph.D., CEO & Chairman of the Board of Coya Therapeutics, Inc. (NASDAQ: COYA), was recently a guest on Benzinga’s All Access. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.